Download PDF
CC BY-NC-ND 4.0 · J Reconstr Microsurg Open 2019; 04(02): e83-e91
DOI: 10.1055/s-0039-3400243
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Contralateral Vascularized Lymph Node Transfer: An Optimized Mouse Model

Giulia Virginia Vottero    *
1   Department of Plastic and Maxillofacial Surgery, University Hospital of Liège, Liège, Belgium
,
Florent Morfoisse‡   *
2   GIGA-Cancer Department, Laboratory of Biology of Tumor and Development, GIGA-Cancer, University of Liège, Liège, Belgium
,
Tania Durré
2   GIGA-Cancer Department, Laboratory of Biology of Tumor and Development, GIGA-Cancer, University of Liège, Liège, Belgium
,
Silvia Blacher
2   GIGA-Cancer Department, Laboratory of Biology of Tumor and Development, GIGA-Cancer, University of Liège, Liège, Belgium
,
Guillaume Becker
3   GIGA-Cyclotron Research Centre/In Vivo Imaging, University of Liège, Liège, Belgium
,
Mohamed A. Bahri
3   GIGA-Cyclotron Research Centre/In Vivo Imaging, University of Liège, Liège, Belgium
,
Alain Plenevaux
3   GIGA-Cyclotron Research Centre/In Vivo Imaging, University of Liège, Liège, Belgium
,
Agnès Noel
2   GIGA-Cancer Department, Laboratory of Biology of Tumor and Development, GIGA-Cancer, University of Liège, Liège, Belgium
,
Jean Luc Nizet
1   Department of Plastic and Maxillofacial Surgery, University Hospital of Liège, Liège, Belgium
› Author Affiliations
Further Information

Publication History

24 April 2019

29 September 2019

Publication Date:
28 November 2019 (online)

Also available at
   Permissions and Reprints

Abstract

Background Vascularized lymph node transfer (VLNT) is one of the surgical options in the treatment of lymphedema, but its mechanism of action has not yet been firmly clarified. In the VLNT mouse models described so far, the lymph node flap is performed between two different sites in the same lymphedematous paw. In this study, we describe an optimized VLNT mouse model using the contralateral paw as donor site, thus removing the bias of transferring a lymph node already damaged by irradiation and/or surgery required to induce lymphedema.

Methods A lymphedema was induced on the left posterior paw in four experimental groups of mice (n = 8). Two weeks later, group 1 was the sham one, group 2 underwent a VLNT from the right inguinal region to the left, in group 3 a vascular endothelial growth factor (VEGF)-C sponge was placed alone in the left inguinal region, and in group 4 a VEGF-C sponge was associated to the VLNT. The 32 mice were followed during 3 months. Outcomes included paws volume, skin quality, inflammation in the lymphedematous tissue, and lymphatic network density and function.

Results Group 4 displayed significantly higher (p < 0.05) lymphedema regression compared with the other three groups.

Conclusions This optimized mouse model of VLNT shows to be handy and effective. It could be exploited to perform further experimental studies about the influence of VLNT on lymphedema. Moreover, the local association between VLNT and biological compounds in this model allows it to be a good preclinical model to identify new potential drugs in lymphedema.

Keywords

lymphedema - mouse model - vascularized lymph node transfer

* These authors contributed equally to this manuscript.


 

  • References

  • 1 Bergan J, Bunke N. General considerations. In: Lee BB, Bergan J, Rockson SG, eds. Lymphedema. A Concise Compendium of Theory and Practice. London: Springer-Verlag; 2011: 3-5
    Search in Google Scholar
  • 2 Koshima I, Narushima M, Yamamoto Y, Mihara M, Iida T. Recent advancement on surgical treatments for lymphedema. Ann Vasc Dis 2012; 5 (04) 409-415
    CrossrefPubMedSearch in Google Scholar
  • 3 Cheng MH, Huang JJ, Wu CW. , et al. The mechanism of vascularized lymph node transfer for lymphedema: natural lymphaticovenous drainage. Plast Reconstr Surg 2014; 133 (02) 192e-198e
    CrossrefPubMedSearch in Google Scholar
  • 4 Scaglioni MF, Arvanitakis M, Chen YC, Giovanoli P, Chia-Shen Yang J, Chang EI. Comprehensive review of vascularized lymph node transfers for lymphedema: Outcomes and complications. Microsurgery 2018; 38 (02) 222-229
    CrossrefPubMedSearch in Google Scholar
  • 5 Frueh FS, Gousopoulos E, Rezaeian F, Menger MD, Lindenblatt N, Giovanoli P. Animal models in surgical lymphedema research--a systematic review. J Surg Res 2016; 200 (01) 208-220
    CrossrefPubMedSearch in Google Scholar
  • 6 Jørgensen MG, Toyserkani NM, Hansen CR. , et al. Quantification of chronic lymphedema in a revised mouse model. Ann Plast Surg 2018; 81 (05) 594-603
    CrossrefPubMedSearch in Google Scholar
  • 7 Najjar M, Lopez Jr MM, Ballestin A. , et al. Reestablishment of lymphatic drainage after vascularized lymph node transfer in a rat model. Plast Reconstr Surg 2018; 142 (04) 503e-508e
    CrossrefPubMedSearch in Google Scholar
  • 8 Cornelissen AJ, Qiu SS, Lopez Penha T. , et al. Outcomes of vascularized versus non-vascularized lymph node transplant in animal models for lymphedema. Review of the literature. J Surg Oncol 2017; 115 (01) 32-36
    CrossrefPubMedSearch in Google Scholar
  • 9 Hayashida K, Yoshida S, Yoshimoto H. , et al. Adipose-derived stem cells and vascularized lymph node transfers successfully treat mouse hindlimb secondary lymphedema by early reconnection of the lymphatic system and lymphangiogenesis. Plast Reconstr Surg 2017; 139 (03) 639-651
    CrossrefPubMedSearch in Google Scholar
  • 10 Ishikawa K, Funayama E, Maeda T. , et al. Changes in high endothelial venules in lymph nodes after vascularized and nonvascularized lymph node transfer in a murine autograft model. J Surg Oncol 2019; 119 (06) 700-707
    CrossrefPubMedSearch in Google Scholar
  • 11 Ishikawa K, Maeda T, Funayama E. , et al. Feasibility of pedicled vascularized inguinal lymph node transfer in a mouse model: a preliminary study. Microsurgery 2019; 39 (03) 247-254
    CrossrefPubMedSearch in Google Scholar
  • 12 Avraham T, Yan A, Zampell JC. , et al. Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-β1-mediated tissue fibrosis. Am J Physiol Cell Physiol 2010; 299 (03) C589-C605
    CrossrefPubMedSearch in Google Scholar
  • 13 Harrell MI, Iritani BM, Ruddell A. Lymph node mapping in the mouse. J Immunol Methods 2008; 332 (1-2): 170-174
    CrossrefPubMedSearch in Google Scholar
  • 14 Oashi K, Furukawa H, Oyama A. , et al. A new model of acquired lymphedema in the mouse hind limb: a preliminary report. Ann Plast Surg 2012; 69 (05) 565-568
    CrossrefPubMedSearch in Google Scholar
  • 15 Jeltsch M, Kaipainen A, Joukov V. , et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276 (5317): 1423-1425
    CrossrefPubMedSearch in Google Scholar
  • 16 Morfoisse F, Renaud E, Hantelys F, Prats AC, Garmy-Susini B. Role of hypoxia and vascular endothelial growth factors in lymphangiogenesis. Mol Cell Oncol 2015; 2 (04) e1024821
    PubMedSearch in Google Scholar
  • 17 Van de Velde M, García-Caballero M, Durré T, Kridelka F, Noël A. Ear sponge assay: a method to investigate angiogenesis and lymphangiogenesis in mice. Methods Mol Biol 2018; 1731: 223-233
    PubMedSearch in Google Scholar
  • 18 Kapur JN, Sahoo PK, Wong AKC. A new method for grey-level picture theresholding using the entropy of the histogram. Comput Image Process. 1985; 29: 273-285
    PubMedSearch in Google Scholar
  • 19 Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010; 140 (04) 460-476
    CrossrefPubMedSearch in Google Scholar
  • 20 Ly CL, Kataru RP, Mehrara BJ. Inflammatory manifestations of lymphedema. Int J Mol Sci 2017; 18 (01) E171
    CrossrefPubMedSearch in Google Scholar
  • 21 Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and management. CA Cancer J Clin 2000; 50 (05) 292-307 , quiz 308–311
    CrossrefPubMedSearch in Google Scholar
  • 22 Boris M, Weindorf S, Lasinkski S. Persistence of lymphedema reduction after noninvasive complex lymphedema therapy. Oncology (Williston Park) 1997; 11 (01) 99-109 , discussion 110, 113–114
    PubMedSearch in Google Scholar
  • 23 Saaristo AM, Niemi TS, Viitanen TP, Tervala TV, Hartiala P, Suominen EA. Microvascular breast reconstruction and lymph node transfer for postmastectomy lymphedema patients. Ann Surg 2012; 255 (03) 468-473
    CrossrefPubMedSearch in Google Scholar
  • 24 Hadamitzky C, Pabst R. Acquired lymphedema: an urgent need for adequate animal models. Cancer Res 2008; 68 (02) 343-345
    CrossrefPubMedSearch in Google Scholar
  • 25 Iwasaki D, Yamamoto Y, Murao N, Oyama A, Funayama E, Furukawa H. Establishment of an acquired lymphedema model in the mouse hindlimb: technical refinement and molecular characteristics. Plast Reconstr Surg 2017; 139 (01) 67e-78e
    CrossrefPubMedSearch in Google Scholar
  • 26 Ghanta S, Cuzzone DA, Mehrara BJ. Animal models of lymphedema. In: Neligan PC, Masia J, Piller N. , eds. Lymphedema. Complete Medical and Surgical Management. Thieme Verlags gruppe; 2016: 583-585
    Search in Google Scholar
  • 27 Tammela T, Saaristo A, Holopainen T. , et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med 2007; 13 (12) 1458-1466
    CrossrefPubMedSearch in Google Scholar
  • 28 Hartiala P, Saaristo AM. Growth factor therapy and autologous lymph node transfer in lymphedema. Trends Cardiovasc Med 2010; 20 (08) 249-253
    CrossrefPubMedSearch in Google Scholar
  • 29 Lähteenvuo M, Honkonen K, Tervala T. , et al. Growth factor therapy and autologous lymph node transfer in lymphedema. Circulation 2011; 123 (06) 613-620
    CrossrefPubMedSearch in Google Scholar
  • 30 Holopainen T, Bry M, Alitalo K, Saaristo A. Perspectives on lymphangiogenesis and angiogenesis in cancer. J Surg Oncol 2011; 103 (06) 484-488
    CrossrefPubMedSearch in Google Scholar
  • 31 Visuri MT, Honkonen KM, Hartiala P. , et al. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study. Angiogenesis 2015; 18 (03) 313-326
    CrossrefPubMedSearch in Google Scholar
  • 32 ClinicalTrials.gov. A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema. Available at: https://clinicaltrials.gov/ct2/show/NCT02994771 . Accessed March 6, 2019
    PubMed